Open Access Peer-reviewed Case Report

Gilles de la Tourette syndrome in Central Africa: A case report

Main Article Content

Marcellin Bugeme
Kegnide Christelle Cadnelle Affognon
Jacques Mbaz Musung
Franck Shongo Omanjelo
Dirk E. Teuwen
Sarah Kilumba Numbi
Jenny Tshijik Ndua
Olivier Mukuku corresponding author
Emmanuel Kiyana Muyumba


Gilles de la Tourette syndrome (GTS), also known as Tourette disorder or Tourette syndrome, is a neurodevelopmental disorder that is characterized by the presence of multiple motor and one or more vocal/phonic tics. These tics are generally more common during childhood and reach a maximum severity between 10 and 12 years. Ticks tend to decrease during late adolescence and adulthood in a majority of patients. We report an observation of GTS diagnosed in a 12-year-old child who was taken care of by clonazepam with a good improvement in its symptomatology. This condition has been reported only very rarely in black sub-Saharan Africans and this is probably the first case of GTS reported in Central Africa.

Gilles de la Tourette syndrome, convulsive tic disorder, clonazepam, Central Africa

Article Details

How to Cite
Bugeme, M., Affognon, K. C. C., Musung, J. M., Omanjelo, F. S., Teuwen, D. E., Numbi, S. K., Ndua, J. T., Mukuku, O., & Muyumba, E. K. (2022). Gilles de la Tourette syndrome in Central Africa: A case report. Advances in General Practice of Medicine, 4(1), 71-73.


  1. Diallo R, Welter ML and Mallet L. Prise en charge th´erapeutique des tics dans la maladie de Gilles de Tourette. Revue Neurologique, 2007, 163(3): 375-386.
  2. Hartmann A, Martino D and Murphy T. Gilles de la Tourette syndrome-A treatable condition? Revue Neurologique, 2016, 172(8-9): 446-454.
  3. Robertson MM. The Gilles De La Tourette syndrome: the current status. Archives of Disease in Childhood – Education and Practice, 2012, 97: 166-175.
  4. Stahl SM and Berger PA. Bromocriptine, physostigmine, and neurotransmitter mechanisms in the dystonias. Neurology, 1982, 32(8): 889-889.
  5. Leckman JF. Tourette’s syndrome. The Lancet, 2002, 360(9345): 1577-1586.
  6. Scharf JM, Miller LL, Mathews CA, et al. Prevalence of Tourette syndrome and chronic tics in the population-based Avon longitudinal study of parents and children cohort. Journal of the American Academy of Child & Adolescent Psychiatry, 2012, 51(2): 192-201.
  7. Robertson MM. The prevalence and epidemiology of Gilles de la Tourette syndrome: Part 1: The epidemiological and prevalence studies. Journal of psychosomatic research, 2008, 65(5): 461-472.
  8. Robertson MM. A personal 35 year perspective on Gilles de la Tourette syndrome: prevalence, phenomenology, comorbidities, and coexistent psychopathologies. The Lancet Psychiatry, 2015, 2(1): 68-87.
  9. Kaim, B. A case of Gilles de la Tourette’s syndrome treated with clonazepam. Brain research bulletin, 1983, 11(2): 213-214.
  10. Bloch MH, Panza KE, Landeros-Weisenberger A, et al. Meta-analysis: treatment of attentiondeficit/ hyperactivity disorder in children with comorbid tic disorders. Journal of the American Academy of Child & Adolescent Psychiatry, 2009, 48(9): 884-893.
  11. Tijero-Merino B, Gomez-Esteban JC and Zarranz JJ. Tics and Gilles de la Tourette syndrome. Revista de neurologia, 2009, 48: S17.
  12. Singer HS, Wendlandt J, Krieger M, et al. Baclofen treatment in Tourette syndrome: a double-blind, placebo controlled, crossover trial. Neurology, 2001, 56: 599-604.
  13. Fourneret P, Desombre H and Broussolle E. Des tics moteurs au syndrome de Gilles de la Tourette: donn´ees actuelles, comorbidit´es et principes de prise en charge th´erapeutique chez l'enfant et l'adolescent. Archives de P´ediatrie, 2014, 21(6): 646-651.